BioSpace News Archive

Acurx Pharmaceuticals, Inc. today announced the pricing of an underwritten initial public offering of 2,500,000 newly-issued shares of its common stock at a price of $6.00 per share.

Slayback Pharma LLC announced today the appointment of Pete A. Meyers as its Chief Financial Officer.

Poxel Presents Results of Two Clinical Studies on its Direct AMP Kinase Activator, the PXL770, a t the International Liver Congress (ILC) ™ 2021.

Dexcom announced today featured research and data presentations that will headline the 81st Scientific Sessions of the American Diabetes Association (ADA) virtual conference held June 25-29, 2021.

Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced PANTHERx Rare Pharmacy has been selected as the exclusive provider of specialty pharmacy services for EXSERVAN™ (riluzole), an oral film formulation of riluzole for the treatment of amyotrophic lateral sclerosis (ALS).

Tirzepatide led to superior A1C and body weight reductions from baseline compared to injectable semaglutide 1 mg in 40-week results from Eli Lilly and Company’s (NYSE: LLY) SURPASS-2 clinical trial, which were simultaneously published today in The New England Journal of Medicine (NEJM)1

- Poster 923-P: Phase 2 clinical study results revealed similar tolerability and time-action profile of Technosphere® Insulin in pediatric subjects as in published data for adults; provides rationale for conducting a Phase 3 study

A new study reveals unmanaged diabetes is a key factor in COVID-19 severity and complications, particularly among Hispanic and Latinx populations.

New data show that the incidence and acuity of type 2 diabetes in children increased significantly during the peak of the COVID-19 pandemic, with more pediatric patients hospitalized from March to December 2020 compared to the same time period in 2019

Veru Inc. today announced that it has enrolled the first patient in its Phase 3 VERACITY clinical trial of sabizabulin, an oral, first-in-class, new chemical entity, androgen receptor transport disruptor (targets and inhibits microtubules to disrupt androgen receptor transport into the nucleus), for metastatic castration and androgen receptor targeting agent resistant prostate cancer.